Cinclus Pharma Total Liabilities
Cinclus Pharma total liabilities. Based on the latest financial reports, Cinclus Pharma (CINPHA) has total liabilities worth Skr221.84 Million SEK (≈ $23.87 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Cinclus Pharma (CINPHA) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Cinclus Pharma (2022–2025)
Total liabilities of Cinclus Pharma from 2022 to 2025. This chart illustrates how Cinclus Pharma's total liabilities have evolved over time, based on quarterly financial data.
Cinclus Pharma Competitors by Total Liabilities
The table below lists competitors of Cinclus Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sunshine Metals Ltd
AU:SHN
|
Australia | AU$2.43 Million |
|
Xplus SA
WAR:XPL
|
Poland | zł19.44 Million |
|
ClimateRock Class A Ordinary Shares
NASDAQ:CLRC
|
USA | $9.82 Million |
|
Global Self Storage Inc
NASDAQ:SELF
|
USA | $17.32 Million |
|
Comet Ridge Ltd
AU:COI
|
Australia | AU$47.06 Million |
|
Cingulate Inc
NASDAQ:CING
|
USA | $12.56 Million |
|
LondonMetric Property Plc
LSE:LMP
|
UK | GBX3.42 Billion |
|
Adisyn Ltd
AU:AI1
|
Australia | AU$1.78 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Cinclus Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cinclus Pharma assets under control.
Liquidity & Leverage Metrics
Cinclus Pharma Total Liabilities Ratios Explained
Cinclus Pharma total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cinclus Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cinclus Pharma (2022–2025)
The table below shows the annual total liabilities of Cinclus Pharma from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr177.16 Million ≈ $19.07 Million |
+287.81% |
| 2024-12-31 | Skr45.68 Million ≈ $4.92 Million |
-73.32% |
| 2023-12-31 | Skr171.21 Million ≈ $18.43 Million |
+190.70% |
| 2022-12-31 | Skr58.90 Million ≈ $6.34 Million |
-- |
About Cinclus Pharma
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in … Read more